<DOC>
	<DOCNO>NCT00002679</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness high-dose sequential chemotherapy adjuvant therapy treat patient stage II stage III breast cancer four positive axillary lymph node .</brief_summary>
	<brief_title>Adjuvant High-Dose , Sequential Chemotherapy Treating Patients With Resected Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate efficacy dose intensive , sequential adjuvant chemotherapy doxorubicin , paclitaxel , cyclophosphamide patient stage II/III resect breast cancer . II . Evaluate toxicity regimen patient . OUTLINE : All patient receive sequential chemotherapy regimens consist 3 course doxorubicin , paclitaxel , cyclophosphamide schedule one course every 14 day . Following completion chemotherapy , patient underwent breast conservation surgery receive radiotherapy . Mastectomy patient 10 positive node T3-4 tumor also eligible delay radiotherapy . Patients hormone receptor positive ( whose receptor status unknown ) treat oral tamoxifen 5 year , begin completion therapy . Patients follow every 3 month 2 year , every 6 month 3 year , yearly . PROJECTED ACCRUAL : At total 90 patient enter .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven adenocarcinoma breast involvement 4 axillary node , include T N1 M0 Concurrent bilateral breast cancer allow Complete resection require Total mastectomy breast conserving surgery Adjuvant radiotherapy plan protocol chemotherapy Clear surgical margin Axillary dissection yield least 9 lymph node Entry require within 8 week definitive surgery Hormone receptor status : Any status PATIENT CHARACTERISTICS : Age : Over 18 Sex : Not specify Menopausal status : Not specify Performance status : Karnofsky 80 % 100 % ECOG 0 1 Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL Hepatic : Bilirubin great 1.5 time normal AST great 2 time normal Alkaline phosphatase great 2 time normal Renal : Creatinine great 1.8 mg/dL OR Creatinine clearance least 60 mL/min Urinalysis normal Cardiovascular : Left ventricular ejection fraction normal MUGA echocardiogram No congestive heart failure require medical therapy No serious arrhythmia No first , second , thirddegree heart block Other : No abnormal CT chest abdomen No uncontrolled infection No serious medical condition would prevent treatment No second malignancy except curatively treat : Nonmelanomatous skin cancer Carcinoma situ cervix Not pregnant Negative pregnancy test Barrier contraception require fertile patient , , 6 month protocol therapy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior systemic chemotherapy Endocrine Therapy : No concurrent hormonal therapy unless unrelated cancer Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics Other : No concurrent medication affect conduction unless cleared cardiologist , e.g . : Beta blocker Digoxin Antiarrhythmia agent Calcium channel blocker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>